A Case of Rapid Progressive Neurosyphilis in Patient with Ankylosing Spondylitis Who Is Treating Anti-interleukin 17A Monoclonal Antibody, Secukinumab
Journal of Rheumatic Diseases
;
: 278-281, 2019.
Artigo
em Inglês
| WPRIM
| ID: wpr-766189
ABSTRACT
Anti-interleukin 17A agent, secukinumab is remarkably effective for treating patients with ankylosing spondylitis. However, the main safety concern of secukinumab is an increased risk of infection. Generally, neurosyphilis occurs a few years after the primary syphilitic infection. Rare cases of progressing to neurosyphilis with a much lower latency were reported. We report a case of rapid progressive neurosyphilis involving hearing loss in both ears in a patient with ankylosing spondylitis who was treated with secukinumab.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Espondilite Anquilosante
/
Interleucina-17
/
Orelha
/
Perda Auditiva
/
Neurossífilis
Limite:
Humanos
Idioma:
Inglês
Revista:
Journal of Rheumatic Diseases
Ano de publicação:
2019
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS